AU2003270274B2 - Live attenuated parasite vaccine - Google Patents

Live attenuated parasite vaccine Download PDF

Info

Publication number
AU2003270274B2
AU2003270274B2 AU2003270274A AU2003270274A AU2003270274B2 AU 2003270274 B2 AU2003270274 B2 AU 2003270274B2 AU 2003270274 A AU2003270274 A AU 2003270274A AU 2003270274 A AU2003270274 A AU 2003270274A AU 2003270274 B2 AU2003270274 B2 AU 2003270274B2
Authority
AU
Australia
Prior art keywords
parasite
tet
attenuated live
gene
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003270274A
Other languages
English (en)
Other versions
AU2003270274A1 (en
Inventor
Theodorus Cornelis Schaap
Nicole Francisca Johanna Van Poppel
Arnoldus Nicolaas Vermeulen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of AU2003270274A1 publication Critical patent/AU2003270274A1/en
Assigned to INTERVET INTERNATIONAL B.V. reassignment INTERVET INTERNATIONAL B.V. Request for Assignment Assignors: AKZO NOBEL N.V.
Application granted granted Critical
Publication of AU2003270274B2 publication Critical patent/AU2003270274B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003270274A 2002-09-20 2003-09-19 Live attenuated parasite vaccine Ceased AU2003270274B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02078953 2002-09-20
EP02078953.3 2002-09-20
PCT/EP2003/010696 WO2004026903A2 (en) 2002-09-20 2003-09-19 Live antenuated parasite vaccine

Publications (2)

Publication Number Publication Date
AU2003270274A1 AU2003270274A1 (en) 2004-04-08
AU2003270274B2 true AU2003270274B2 (en) 2009-03-19

Family

ID=32011015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003270274A Ceased AU2003270274B2 (en) 2002-09-20 2003-09-19 Live attenuated parasite vaccine

Country Status (8)

Country Link
US (1) US20050244437A1 (enExample)
EP (1) EP1543028A2 (enExample)
JP (1) JP2006518184A (enExample)
CN (1) CN100393866C (enExample)
AU (1) AU2003270274B2 (enExample)
BR (1) BR0313994A (enExample)
CA (1) CA2498604A1 (enExample)
WO (1) WO2004026903A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004309380B2 (en) 2003-12-19 2010-04-29 Seattle Biomedical Research Institute Live genetically attenuated malaria vaccine
US7722860B2 (en) 2004-12-03 2010-05-25 Seattle Biomedical Research Institute Live genetically engineered protozoan vaccine
ES2319242B1 (es) 2005-12-23 2009-12-01 Laboratorios Hipra, S.A. Aislado avirulento de neospora canimum y sus usos.
WO2009023308A2 (en) * 2007-05-04 2009-02-19 The United States Of America, As Represented By The Secretary Of Agriculture Genetically modified babesia parasites expressing protective tick antigens and uses thereof
ES2326770B1 (es) 2007-07-13 2010-07-26 Universidad Complutense De Madrid Uso de un nuevo aislado de neospora caninum para el desarrollo de pruebas de diagnostico y para la fabricacion de productos para el tratamiento y prevencion de la infenccion causada por neospora.
RU2525587C2 (ru) 2008-05-29 2014-08-20 Интервет Интернэшнл Б.В. Вакцинная композиция для иммунизации животного против кокцидиоза и способ ее использования
AU2009314192A1 (en) * 2008-11-13 2010-05-20 Intervet International B.V. Eimeria vaccine for turkeys
MX2012000675A (es) * 2009-07-13 2012-06-08 Leti Sl Lab Diagnostico de una parasitosis tal como la leishmaniasis usando un extracto de proteinas ribosomicas (rpe).
EP2412382A1 (en) 2010-07-29 2012-02-01 University Court of the University of Edinburgh Recombinant Trypanosoma theileri parasite
WO2012031076A1 (en) * 2010-09-02 2012-03-08 Ludwig Institute For Cancer Research, Ltd. Recombinant trypanosoma cruzi cells useful as anti-cancer immune agents
US20130287786A1 (en) 2010-12-29 2013-10-31 Theodorus Petrus Maria Schetters Canine babesiosis vaccine antigen
US10864260B2 (en) 2015-10-28 2020-12-15 Universidad Complutense De Madrid Neospora vaccine composition
EP3478301A4 (en) 2016-06-29 2020-04-22 Ramot at Tel-Aviv University Ltd. Manipulated parasites for the delivery of protein to the central nervous system (CNS)
WO2019140136A1 (en) * 2018-01-10 2019-07-18 University Of Washington Malarial vaccination methods and regimens
JP7032965B2 (ja) * 2018-03-13 2022-03-09 共立製薬株式会社 反芻動物のネオスポラ感染症に対するワクチン製剤
AU2019271310B2 (en) * 2018-05-15 2023-02-02 The University Of Melbourne Parasite vaccine
CN109825514A (zh) * 2019-01-24 2019-05-31 华中农业大学 田鼠巴贝斯虫gpi10基因及其编码的蛋白和应用
CN110922491B (zh) * 2019-12-17 2021-08-27 河南科技大学 一种肉孢子虫融合抗原、编码基因、间接elisa抗体检测试剂盒及其应用
US12144853B2 (en) 2020-01-13 2024-11-19 University Of Washington Targeted vaccination in the liver

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756662A (en) * 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
EP0876497A1 (en) * 1995-12-22 1998-11-11 E.I. Du Pont De Nemours And Company Production of recombinant baculoviruses
US6596508B2 (en) * 1999-03-19 2003-07-22 National Research Council Of Canada CRE-inducible expression system
WO2000066154A2 (en) * 1999-05-04 2000-11-09 Arch Development Corporation Anti-microbial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression

Also Published As

Publication number Publication date
EP1543028A2 (en) 2005-06-22
CN1681842A (zh) 2005-10-12
JP2006518184A (ja) 2006-08-10
AU2003270274A1 (en) 2004-04-08
WO2004026903A2 (en) 2004-04-01
US20050244437A1 (en) 2005-11-03
CA2498604A1 (en) 2004-04-01
WO2004026903A3 (en) 2004-06-03
BR0313994A (pt) 2005-07-19
CN100393866C (zh) 2008-06-11

Similar Documents

Publication Publication Date Title
AU2003270274B2 (en) Live attenuated parasite vaccine
Waters et al. Transfection of malaria parasites
US20090196888A1 (en) Nucleic acids encoding recombinant 56 and 82 kDa antigents from gametocytes of Eimeria maxima and their uses
Yang et al. NcGRA17 is an important regulator of parasitophorous vacuole morphology and pathogenicity of Neospora caninum
US7026156B1 (en) Diagnostic and protective antigen gene sequences of ichthyophthirius
EP0553117A1 (en) Genetically engineered coccidiosis vaccine
EP1151118B1 (en) Recombinant expression of heterologous nucleic acids in protozoa
US6846481B1 (en) Recombinant expression of heterologous nucleic acids in protozoa
JPH03505970A (ja) 遺伝子工学によるコクシジウム症ワクチン
EP2598163B1 (en) Recombinant trypanosoma theileri parasite
KR0152245B1 (ko) 에이메리아 테넬라 왁찐
US20050106164A1 (en) Recombinant expression of heterologous nucleic acids in protozoa
Zhu et al. Identification and characterization of a cDNA clone-encoding antigen of Eimeria acervulina
Soete et al. The importance of reverse genetics in determining gene function in apicomplexan parasites
CN111032079A (zh) 双重减毒肝晚期疟原虫及相关组合物和方法
WO2013113865A1 (en) Eimeria vector vaccine for campylobacter jejuni
US20100093062A1 (en) Transfection system for perkinsus species
Gaylets The Apicomplexan-Specific FIKK Kinase is Crucial for Cyst Formation in Toxoplasma gondii
JP2004520277A (ja) 胞子虫網（ａｐｉｃｏｍｐｌｅｘａｎ）寄生虫からの細胞侵入因子に基づくワクチン
Wand et al. Variant surface glycoprotein synthesis and cell cycle progression in Trypanosoma brucei
Adhikari Construction of transfection vectors to target plasmodium berghei Apical membrane antigen1 (AMA1) and autophagy related 18 (ATG18) genes, and characterization of recombinant parasites
Shah Identification of genes encoding secreted proteins of schistosomes.
Laughery Stable expression of GFP-BSD and surface exposed BM86 epitopes in transfected B. bovis merozoites
Ghoneim Recombinant expression of the rhoptry protein Clag3. 1 as a green fluorescent chimeric protein in Plasmodium falciparum
Ververken The polymorphic immunodominant molecule of Theileria parva: recombinant expression and localization in mammalian cells, DNA immunization of cattle and use in diagnosis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ LIVE ATTENUATED PARASITE VACCINE

PC1 Assignment before grant (sect. 113)

Owner name: INTERVET INTERNATIONAL B.V.

Free format text: FORMER APPLICANT(S): AKZO NOBEL N.V.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired